Cargando…

Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial

This study sought to evaluate the efficacy of the isolated use of fluorometholone compared with the combined use of azelastine and fluorometholone for the treatment of severe allergic conjunctival disease (ACD). One hundred and eleven patients with severe ACD were randomized into two groups: one tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Minjie, Ke, Bilian, Zou, Jun, Gong, Lan, Wang, Yan, Zhang, Chaoran, Xu, Jianjiang, Wei, Anji, Hong, Jiaxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267215/
https://www.ncbi.nlm.nih.gov/pubmed/35807160
http://dx.doi.org/10.3390/jcm11133877
_version_ 1784743663833710592
author Chen, Minjie
Ke, Bilian
Zou, Jun
Gong, Lan
Wang, Yan
Zhang, Chaoran
Xu, Jianjiang
Wei, Anji
Hong, Jiaxu
author_facet Chen, Minjie
Ke, Bilian
Zou, Jun
Gong, Lan
Wang, Yan
Zhang, Chaoran
Xu, Jianjiang
Wei, Anji
Hong, Jiaxu
author_sort Chen, Minjie
collection PubMed
description This study sought to evaluate the efficacy of the isolated use of fluorometholone compared with the combined use of azelastine and fluorometholone for the treatment of severe allergic conjunctival disease (ACD). One hundred and eleven patients with severe ACD were randomized into two groups: one treated with topical 0.1% fluorometholone combined with 0.05% azelastine and the other with 0.1% fluorometholone alone. The Ocular Surface Disease Index (OSDI) and the signs of keratopathy, palpebral conjunctiva papillae and conjunctival congestion were scored before and at one, two and six weeks after treatment and compared between the groups. The intra-ocular pressure (IOP) was also monitored. There were no significant differences between the groups in the baseline mean scores of signs and OSDI scores, which gradually improved at all visits after therapy in both groups. Although the time effect was significant for all the parameters (all p < 0.001), the reduction in corneal involvement scores from week 2 to week 6 was insignificant in both groups (p = 0.460 for the steroids group and p = 0.074 for the combination group). All signs and symptoms were significantly more improved in the combination group than in the isolated group at each control visit. IOP remained stable at all visits (all p < 0.001), except one patient in each group had elevated IOP over 21 mmHg. While both the isolated use of fluorometholone and combined use of azelastine and fluorometholone are effective in alleviating the signs and symptoms of severe ACD, optimal response can be achieved with adjunctive treatment including azelastine.
format Online
Article
Text
id pubmed-9267215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92672152022-07-09 Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial Chen, Minjie Ke, Bilian Zou, Jun Gong, Lan Wang, Yan Zhang, Chaoran Xu, Jianjiang Wei, Anji Hong, Jiaxu J Clin Med Article This study sought to evaluate the efficacy of the isolated use of fluorometholone compared with the combined use of azelastine and fluorometholone for the treatment of severe allergic conjunctival disease (ACD). One hundred and eleven patients with severe ACD were randomized into two groups: one treated with topical 0.1% fluorometholone combined with 0.05% azelastine and the other with 0.1% fluorometholone alone. The Ocular Surface Disease Index (OSDI) and the signs of keratopathy, palpebral conjunctiva papillae and conjunctival congestion were scored before and at one, two and six weeks after treatment and compared between the groups. The intra-ocular pressure (IOP) was also monitored. There were no significant differences between the groups in the baseline mean scores of signs and OSDI scores, which gradually improved at all visits after therapy in both groups. Although the time effect was significant for all the parameters (all p < 0.001), the reduction in corneal involvement scores from week 2 to week 6 was insignificant in both groups (p = 0.460 for the steroids group and p = 0.074 for the combination group). All signs and symptoms were significantly more improved in the combination group than in the isolated group at each control visit. IOP remained stable at all visits (all p < 0.001), except one patient in each group had elevated IOP over 21 mmHg. While both the isolated use of fluorometholone and combined use of azelastine and fluorometholone are effective in alleviating the signs and symptoms of severe ACD, optimal response can be achieved with adjunctive treatment including azelastine. MDPI 2022-07-04 /pmc/articles/PMC9267215/ /pubmed/35807160 http://dx.doi.org/10.3390/jcm11133877 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Minjie
Ke, Bilian
Zou, Jun
Gong, Lan
Wang, Yan
Zhang, Chaoran
Xu, Jianjiang
Wei, Anji
Hong, Jiaxu
Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
title Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
title_full Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
title_fullStr Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
title_full_unstemmed Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
title_short Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
title_sort combination therapy of 0.1% fluorometholone and 0.05% azelastine in eyes with severe allergic conjunctival diseases: a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267215/
https://www.ncbi.nlm.nih.gov/pubmed/35807160
http://dx.doi.org/10.3390/jcm11133877
work_keys_str_mv AT chenminjie combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT kebilian combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT zoujun combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT gonglan combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT wangyan combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT zhangchaoran combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT xujianjiang combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT weianji combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial
AT hongjiaxu combinationtherapyof01fluorometholoneand005azelastineineyeswithsevereallergicconjunctivaldiseasesarandomizedcontrolledtrial